Biosimilars global spending set to reach $2.5 Billion by 2015, according to an IMS forecast

Following the success of our past events, SMi’s third Biosimilars and Biobetters conference will build upon the progress made in previous meetings and further develop the ideas and strategies that were debated and discussed. In particular how industry players will face regulatory challenges in approval of follow on biologics, rising development costs, threat from competition and a similar if not bigger challenge to that seen in marketing of innovator drugs.

There will be case studies from those who are both developing and distributing follow on biologics. With analysis of key trends in biologic pipelines, methods in clinical trials for biosimilar approval, a review of emerging markets, assessment of biosimilar manufacturing, post approval strategy and future forecasting for follow on biologics.

SMi’s Biosimilars and Biobetters event will provide up to date information from key opinion leaders in the biologics industry with discussion and debate and opportunities for networking between CROs, CMOs, law firms, regulatory bodies, pharma and biotechs.

If you are interested in speaking at the conference, please contact smiproduction@smi-online.co.uk

For sponsorship and exhibition opportunities, please contact sponsorshipdept@smi-online.co.uk  

Why should you attend this event?

 

Hear talks from key opinion leaders on regulatory issues, pipelines, emerging markets, manufacturing and distribution Witness a strong focus on pioneering topics that will expose commercial opportunities for future investments Recieve in depth analysis of the biosimilars market relevant to buyers and sellers alike Experience a platform for networking between solution providers, pharma and biotechs Be part of real progress towards the future of accessible medicines and partake in discussion about key developments important to all with a vested interest in follow on biologics

Hear keynote addresses from:

Laura McKinley, Director Worldwide Regulatory Strategy, Pfizer

Andrew Rankin, Head of Clinical Development, Teva Pharmaceuticals

Our expert speaker line-up also includes:

Sreedhar Sagi, Risk Management Compliance Officer Biopharmaceuticals Development, Sandoz
Richard DiCicco, Chairman, Harvest Moon Pharmaceuticals USA, Inc
Heinz Haenel, Senior Project Director, Sanofi Aventis
Anne Dollard, Chief Patent Counsel, Deputy General Counsel, Takeda Pharmaceuticals
Sandy Eisen, Chief Medical Officer, former CMO, Frontline Pharma Consulting, Teva Pharmaceuticals
Paul Greenland, EMEA Director of Biosimilars and Proprietary Marketing, Hospira
David Szymkowski, Senior Director, Research, Biotherapeutics, Xencor, Inc
Steve Brocchini, CSO, PolyTherics Ltd.
Nicola Travierso, General Manager, NTC SRL
Christopher Stothers, Partner, Arnold and Porter LLP
Peter Wittner, Senior Consultant, Interpharm Consultancy
Ori Hershkovitz, Partner and Head of Pharmaceutical Research, Sphera Global Healthcare Fund

Who should attend?

Chief Executives, Executive Directors, Vice Presidents, Heads and Team Leaders from:

• Intellectual Property
• Legislation and Policy Advice
• Business Development
• Licensing
• Manufacturing
• APIs
• Bioequivalence
• Drug and Safety Assessment
• Market Strategy
• Regulatory Affairs